This article is about a legal dispute between PharmAthene (NYSEMKT:PIP) and SIGA (NASDAQ:SIGA) that I discussed in a previous article, and in its predecessor, both of which relate to a 2011 ruling by Vice Chancellor Parsons, and the Delaware Supreme Court's May 24, 2013 response, which remanded damages-related issues to the Vice Chancellor. On June 26, the Vice Chancellor held a status conference to discuss how to proceed. Below I describe what happened during the meeting that is relevant to valuing PharmAthene, discuss a new legal issue introduced and describe a damages remedy that, I argue, would be more equitable, less likely to be subject to manipulation by SIGA, and less susceptible to be...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|